StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3034% above fair value
$91.35−1.69 (-1.82%)

Close on Nov 20, 2026Market cap $10.37BP/E 26.9Yield –

Halozyme Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Halozyme Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $1.66B, up 41.2% year over year. For fiscal 2025 it was $1.40B, up 37.6% from the year before. Over ten years it grew 26.3% a year on average. The highest annual figure on record is $1.40B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.40B+37.6%
FY2024Dec 31, 2024$1.02B+22.4%
FY2023Dec 31, 2023$829.25M+25.6%
FY2022Dec 31, 2022$660.12M+48.9%
FY2021Dec 31, 2021$443.31M+65.7%
FY2020Dec 31, 2020$267.59M+36.5%
FY2019Dec 31, 2019$195.99M+29.1%
FY2018Dec 31, 2018$151.86M-52.0%
FY2017Dec 31, 2017$316.61M+115.8%
FY2016Dec 31, 2016$146.69M+8.6%
FY2015Dec 31, 2015$135.06M+79.3%
FY2014Dec 31, 2014$75.33M+37.5%
FY2013Dec 31, 2013$54.80M+29.5%
FY2012Dec 31, 2012$42.33M-24.5%
FY2011Dec 31, 2011$56.09M+311.7%
FY2010Dec 31, 2010$13.62M-0.3%
FY2009Dec 31, 2009$13.67M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$481.00M+47.7%
Q1 FY2026Mar 31, 2026$376.71M+42.2%
Q4 FY2025Dec 31, 2025$451.77M+51.6%
Q3 FY2025Sep 30, 2025$354.26M+22.1%
Q2 FY2025Jun 30, 2025$325.72M+40.8%
Q1 FY2025Mar 31, 2025$264.86M+35.2%
Q4 FY2024Dec 31, 2024$298.01M+29.5%
Q3 FY2024Sep 30, 2024$290.08M+34.3%
Q2 FY2024Jun 30, 2024$231.35M+4.7%
Q1 FY2024Mar 31, 2024$195.88M+20.8%
Q4 FY2023Dec 31, 2023$230.04M+26.7%
Q3 FY2023Sep 30, 2023$216.03M+3.4%
Q2 FY2023Jun 30, 2023$221.04M+45.1%
Q1 FY2023Mar 31, 2023$162.14M+38.3%
Q4 FY2022Dec 31, 2022$181.50M+77.9%
Q3 FY2022Sep 30, 2022$208.98M+80.4%
Q2 FY2022Jun 30, 2022$152.37M+11.7%
Q1 FY2022Mar 31, 2022$117.28M+31.7%
Q4 FY2021Dec 31, 2021$102.00M-16.2%
Q3 FY2021Sep 30, 2021$115.83M+77.3%
Q2 FY2021Jun 30, 2021$136.46M+147.1%
Q1 FY2021Mar 31, 2021$89.02M+251.1%
Q4 FY2020Dec 31, 2020$121.70M+126.8%
Q3 FY2020Sep 30, 2020$65.32M+41.3%
Q2 FY2020Jun 30, 2020$55.22M+41.1%
Q1 FY2020Mar 31, 2020$25.35M-55.5%
Q4 FY2019Dec 31, 2019$53.67M-10.9%
Q3 FY2019Sep 30, 2019$46.23M+80.9%
Q2 FY2019Jun 30, 2019$39.15M+11.2%
Q1 FY2019Mar 31, 2019$56.95M+84.5%
Q4 FY2018Dec 31, 2018$60.23M-68.2%
Q3 FY2018Sep 30, 2018$25.56M-59.9%
Q2 FY2018Jun 30, 2018$35.20M+4.3%
Q1 FY2018Mar 31, 2018$30.87M+4.4%
Q4 FY2017Dec 31, 2017$189.56M+386.0%
Q3 FY2017Sep 30, 2017$63.73M+100.1%
Q2 FY2017Jun 30, 2017$33.75M–
Q1 FY2017Mar 31, 2017$29.57M–
Q4 FY2016Dec 31, 2016$39.00M–
Q3 FY2016Sep 30, 2016$31.85M–

More Halozyme Therapeutics figures

See a number that looks wrong?